Illumina Announces NovaSeq X Updates With Single-Flow-Cell System, Software Upgrade, New Kits Enhancing Multiomic Capabilities
Illumina Announces NovaSeq X Updates With Single-Flow-Cell System, Software Upgrade, New Kits Enhancing Multiomic Capabilities
Software upgrade advances complete workflow solutions
软件升级推进完整的工作流程解决方案
New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep
新的NovaSeq X 250亿100次循环和200次循环套件增强了NovaSeq X的多组学能力,并支持新发布的Illumina单细胞准备。
SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits.
圣地亚哥,2025年1月7日 /PRNewswire/ -- Illumina公司(纳斯达克:ILMN),全球DNA测序和阵列技术的领先者,今天宣布对其NovaSeq X系列进行一系列更新,推出NovaSeq X单电芯系统,并配备尖端软件升级和新套件。
Now in the market for the first time, the single-flow-cell NovaSeq X Sequencing System offers the same high-quality flow cells and speed as the NovaSeq X Plus Sequencing System—Illumina's most rapidly adopted and utilized high-throughput sequencing platform to date—at a more accessible cost for labs with lower volume. The sequencers began shipping in December, and simultaneously the company introduced the software v1.3 upgrade for the NovaSeq X Series to elevate sequencing performance and advance data quality. Additionally, new NovaSeq X 25B 100- and 200-cycle kits began shipping in December, which will be key enablers of multiomic applications, including the Illumina Single-Cell 3' RNA Prep (Illumina Single Cell Prep), now available under Illumina's brand following the company's acquisition of Fluent.
现在首次上市的单电芯NovaSeq X测序系统提供与NovaSeq X Plus测序系统相同的高质量电芯和速度——Illumina迄今为止最被快速采用和使用的高通量测序平台——以对低成交量实验室更可接受的成本。测序仪于12月开始发货,同时公司推出了NovaSeq X系列的软件v1.3升级,以提升测序性能和提高数据质量。此外,新的NovaSeq X 250亿100次和200次循环套件于12月开始发货,这将是多组学应用的关键推动因素,包括现在在Illumina品牌下可获得的Illumina单细胞3' RNA准备(Illumina单细胞准备),该项技术是在公司收购Fluent后推出的。